z-logo
open-access-imgOpen Access
Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome
Author(s) -
Tomoko Horinouchi,
Kandai Nozu,
Tomohiko Yamamura,
Shogo Minamikawa,
Takashi Omori,
Keita Nakanishi,
Junya Fujimura,
Akira Ashida,
Mineaki Kitamura,
Mitsuhiro Kawano,
Wataru Shimabukuro,
Chizuko Kitabayashi,
Aya Imafuku,
Keiichi Tamagaki,
Koichi Kamei,
Kenjirou Okamoto,
Shuichiro Fujinaga,
Masafumi Oka,
Toru Igarashi,
Akinori Miyazono,
Emi Sawanobori,
Rika Fujimaru,
Koichi Nakanishi,
Yuko Shima,
Masafumi Matsuo,
Ming Juan Ye,
Yoshimi Nozu,
Naoya Morisada,
Hiroshi Kaito,
Kazumoto Iijima
Publication year - 2018
Publication title -
journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.451
H-Index - 279
eISSN - 1533-3450
pISSN - 1046-6673
DOI - 10.1681/asn.2018030228
Subject(s) - medicine , rna splicing , exon , alport syndrome , alternative splicing , phenotype , genotype , mutation , gene , genetics , biology , glomerulonephritis , kidney , rna
Background X-linked Alport syndrome (XLAS) is a progressive hereditary nephropathy caused by mutations in the COL4A5 gene. Genotype-phenotype correlation in male XLAS is relatively well established; relative to truncating mutations, nontruncating mutations exhibit milder phenotypes. However, transcript comparison between XLAS cases with splicing abnormalities that result in a premature stop codon and those with nontruncating splicing abnormalities has not been reported, mainly because transcript analysis is not routinely conducted in patients with XLAS. Methods We examined transcript expression for all patients with suspected splicing abnormalities who were treated at one hospital between January of 2006 and July of 2017. Additionally, we recruited 46 males from 29 families with splicing abnormalities to examine genotype-phenotype correlation in patients with truncating ( n =21, from 14 families) and nontruncating ( n =25, from 15 families) mutations at the transcript level. Results We detected 41 XLAS families with abnormal splicing patterns and described novel XLAS atypical splicing patterns ( n =14) other than exon skipping caused by point mutations in the splice consensus sequence. The median age for developing ESRD was 20 years (95% confidence interval, 14 to 23 years) among patients with truncating mutations and 29 years (95% confidence interval, 25 to 40 years) among patients with nontruncating mutations ( P =0.001). Conclusions We report unpredictable atypical splicing in the COL4A5 gene in male patients with XLAS and reveal that renal prognosis differs significantly for patients with truncating versus nontruncating splicing abnormalities. Our results suggest that splicing modulation should be explored as a therapy for XLAS with truncating mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom